This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.

Solifenacin is an anticholinergic drug that is commonly used for lower urinary tract symptoms such as urgency, frequency and urge urinary incontinence. Solifenacin use and sexual function improvement is presented in some research, but the correlation between the improvement in sexual function and LUTS symptoms is yet not investigated. Also the effect on sexual function in premenopausal vs postmenopausal women are unknown.

Inclusion Criteria:

• Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg).
• Patients agreed to involve in the study, having discussed other treatment options and possible side effects of the medication.
• Informed consent obtained

Exclusion Criteria:

• urinary tract infection
• stress urinary incontinence
• urinary retention
• grade 2 or above pelvic organ prolapse according to POP-Q scale
• Solifenacin contraindications such as narrow angle glaucoma, allergy of Solifenacin or other components of the drug.

Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg) are enrolled in the study.